Abbott Laboratories closed 10.57% short of its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

The decision to allow a new trial could have  implications for both the companies and families with babies born prematurely.

Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could pursue a new ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Today, Benzinga 's options scanner spotted 10 uncommon options trades for Abbott Laboratories. This isn't normal. The overall ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Abbott Laboratories (ABT – Research Report) and ...

We recently published a list of Friday’s 10 Worst Performing Stocks. In this article, we are going to take a look at where ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other best ...

Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories (NYSE:ABT). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Abbott Laboratories and Reckitt Benckiser Group Plc shares fell as a judge ordered a new trial after rejecting a verdict that ...